Key Highlights

  • Micro-X shares rose 4% to AUD 0.026 on 2 September 2026.
  • The company is developing CT and X-ray systems around its Nano Electronic X-ray technology.
  • A lung CT research program includes AUD 1.3mn allocated to Micro-X.
  • The company is also progressing human imaging and portable full-body CT programs.

Micro-X Ltd (ASX: MX1) is drawing fresh market attention after its shares rose 4.00% to AUD 0.026 on 2 September 2026. The company’s Market Capitalisation stood at AUD 19.56mn, while its one-year share performance was -66.67%. The latest move puts the stock back in focus as investors assess its operating progress, recent company developments and the milestones that could shape the next phase of its story.

A Medical Imaging Platform With Multiple Applications

Micro-X develops and commercialises imaging products for global health and security markets. Its Nano Electronic X-ray technology forms the core of its product platform, using proprietary high-voltage X-ray tubes and generators. The company’s strategy is to apply this technology across portable and specialised imaging applications.

CT Development Is Moving Into Human Studies

Micro-X’s July 2026 investor newsletter highlighted progress across its Head CT human imaging trial, portable Full Body CT development and Lung CT research. The company views these programs as extensions of a common technology platform developed over more than a decade. That platform approach is important because successful technical development in one application can potentially support further product opportunities.

Lung CT Program Adds Another Potential Market

In June, Micro-X announced its involvement in a laboratory lung CT scanner test bench with the University of Sydney. The wider research program has AUD 1.9mn awarded to project partners, including AUD 1.3mn to Micro-X. The work is aimed at developing a proof-of-concept test bench for early lung cancer detection and builds on earlier feasibility work.

Shares Gain From a Low Base

Micro-X shares traded at AUD 0.026 on 2 September 2026, up 4.00%. The company’s market capitalisation was AUD 19.56mn, while the one-year performance was -66.67%. The latest gain therefore comes after a difficult twelve-month period. Investors are likely to focus on technical milestones and commercial progress as the company works to translate its platform into products.

From Technology to Commercialisation

Micro-X has a portfolio that spans medical and security imaging. In healthcare, portable CT and mobile imaging are designed to support more decentralised care, including potential use in ambulances and remote settings. The company’s vertically integrated Adelaide Facility and technical presence in the United States provide the base for further development.

A Measured View on Risk

Micro-X’s programs remain development-intensive, and technical validation, regulatory progress, Manufacturing and customer adoption will determine how quickly opportunities can become commercial products. The company is pursuing several programs simultaneously, which creates opportunity but also requires careful allocation of funding and engineering resources.